treatment pattern f or patients wit h HCC has gradually evolved from previous surgical treatment alone to the current multidisciplinary specialization minimally invasive comprehensive treatment [1, 2] . Transcatheter arterial chemoembolization (TACE) combined with imageguided radiofrequency ablation (RFA) is one of the comprehensive strategies and has obtained good efficacy in treating patients with HCC [3] . However, due to combined with hepatitis and sclerosis in HCC patients and the biologic characteristics of multicenter origins occurs synchronously or heterochronously [4, 5] , as well as the disorders of immune functions in patients with tumors [6] , recurrent rates are higher even with curative treatment. The efficacy of the curative treatment is thus compromised. Therefore, the investigation for an effective method to strengthen treatment efficacy and to prevent and inhibit the recurrence of HCC is a hot issue in the research of HCC.
Studies have suggested that the factors and potential mechanisms may vary for recurrence developed at different time points after treatment for HCC. Longterm recurrence may be due to new lesions originating from varying HCC clones, but shortterm recurrence is probably due to uncontrolled local tumors and micrometastatic lesions derived from tumor clones. Therefore, an important step in preventing recurrence is to improve local control and eradicate micrometastatic lesions [7] . Minimally invasive therapy is particularly useful in terms of local control, while cell immune therapy exerts a wide range of antitumor activities by mechanisms of action that include improving immune functions in the body and directly eradicating residual tumor cells in the patients. Cytokineinduced killer (CIK) cells are one of these immune therapies and present potent proliferation in vivo as well as strong antitumor activity. Clinical studies have demonstrated that it is an excellent method to prevent tumor recurrence and has preliminarily shown its efficacy in inhibiting recurrence and metastasis of primary HCC [8, 9] . Moreover, among numerous factors that predict HCC recurrence, alphafetoprotein (AFP) has been proved by a body of EBM evidence to be in close correlation with recurrence [7, 10] . AFP is a protein that can be expressed by hepatic cancer cells, with extremely complicated biologic activities. Studies have shown that AFP plays double roles in both inhibiting the immune system and promoting the growth of cancer cells. For the time being, it is still unclear whether such roles have an effect in HCC recurrence. Although 10% 30% of patients with HCC have negative AFP expression, most investigators believe that AFP is significant in predicting HCC recurrence and evaluating the biologic features of tumors and treatment regimens. Recent studies have gradually established the role of AFP as a tool in evaluating efficacy of systemic chemotherapy for patients with advanced HCC [11, 12] , but no studies have been reported regarding its role as a tool for evaluating the efficacy as a biologic therapy.
Herein we investigated the efficacy of adoptive cell immunotherapy combined with curative minimally invasive therapies in preventing HCC recurrence after minimally invasive therapy and monitored the changes in serum AFP values during CIK cell therapy in a randomized controlled study, which revealed that CIK cells eradicated residual cancer cells and prompted a decrease of AFP value from the upper limit of the normal range to the lower limit of normal after CIK cells therapy, to investigate the significance of AFP as a marker in evaluating clinical efficacy of CIK cells.
Between July 2002 and August 2008, 122 selected patients with HCC were treated using TACE with combined sequential RFA therapy at the Center of Medical Radiology and Intervention in Sun Yatsen University Cancer Center.
Inclusion criteria included (1) all patients provided informed consent for the therapies before inclusion; (2) diagnostic criteria for HCC: the patient fulfilled the Clinical Diagnostic Criteria for HCC in 2001 and was ratable by the clinical staging system. For patients diagnosed after 2005, the American Association for the Study of Liver Disease (AASLD) criteria was adopted [13] ; (3) all patients had their liver function parameters within normal ranges and had an AFP value higher than the normal reference value (25 ng/mL) when first diagnosed; (4) computed tomography (CT) scanning suggested major intrahepatic tumors were massshaped. For those with multiple cancer nodules, the number of nodules was should be no more than 3; (5) radiology suggested no cancer embolus formation in the inferior vena cava or the portal vein, and no distant metastasis was identified; (6) at 6 to 8 weeks after TACE and sequential RFA therapy, the possibility of residual tumors was excluded by contrastenhanced CT scanning, enhanced magnetic resonance imaging (MRI) examination, or positron emission tomography (PET)/CT together with the results of clinical examinations. In addition, AFP level fell back to normal range or remained higher than the reference value but lower than 1.5 times of the upper limit of the reference value (that is, < 37.5 ng/mL), however digital subtraction angiography (DSA) suggested no intrahepatic tumor blush; and (7) before randomization, two consecutive AFP determinations, with at least a 1week interval between them, suggested that the AFP concentration was stable (variation of less than 50%).
TACE was performed with DSA (Toshiba Corporation, BLA 800A). The CT scanning system used was a Marconi CTtwin flash at the scanning conditions: 120 kV; 265 mAs; slice thickness: 810 mm; and pitch: 1. RFA systems were WE7568 multipolar radiofrequency ablation systems for tumors at the pulse power of 400 W and the pulse frequency of 290 kHz, or a monopolar cooltip therapy system (CoolTip; Valleylab, MA, USA). For selective TACE therapy, the routine mixture emulsion of pirarubicin (5060 mg), mitomycin (810 mg), cisplatin (2060 mg), oil solution and iodized oil (1020 mL) was used (in each specific case, the dose of the drugs mentioned above might be modified as appropriate according to tumor size and tumor blood supply).
After the RFA procedure for HCC, CIK cells were prepared in accordance with the routine operations in our biologic therapy center. When final preparation of the CIK cells fulfilled the criteria of acceptability at our center [9] , CIK cells infusion was performed once every week, with a total of at least 4 infusions and more than 1 伊 10 10 cells for each infusion. Infusion was given via common hepatic artery or peripheral veins.
After curative TACE combined with RFA therapy, routine liver protection and supportive treatments were given, and patients were randomly assigned and included for CIK cell therapy when liver functions were within normal ranges.
Patients underwent routine AFP examinations after being admitted, at 1 week and 4 weeks after TACE and sequential RFA procedures. In the study group, AFP detection was performed before each CIK cell therapy and once every 4 weeks within 1 year after the end of CIK cell therapy. For the control group, AFP detection was performed once every 4 weeks within 1 year after minimally invasive therapy. After 1year followup, AFP detection was performed once every 2 months for all patients.
In the study group, 2 mL blood was obtained in peripheral blood before CIK cell therapy and after at least 2 CIK cell infusions for routine detection of lymphocyte subsets.
Patients were followed up for at least 1 year, during which the tumor was evaluated once every 12 months. After the first year, the tumor was evaluated to once every 23 months with followup contrastenhanced liver CT scanning (those who were allergic to contrast media could be given enhanced MRI scanning) and routine biochemical tests, HBVDNA content, chest Xray together with the results of AFP detections, to determine whether recurrence developed. When the determination was not possible, ultrasonography and MRI would be used in combination, and local biopsy could be performed when necessary.
AFP data obtained before and after treatment and during followup were presented as mean 依 standard deviation (SD) and were described and analyzed by the SPSS version 15.0, with the study design of a test for selfpaired means. The 1year recurrent rates in the study and control groups were analyzed with a 字 2 test. A value of less than 0.05 was considered as statistically significant.
A total of 83 patients met inclusion criteria and were randomly assigned using sealed envelopes into two groups: the study group ( = 42) and the control group ( = 41). Of the 83 patients, 81 completed the followup and 2 patients in the control group were lost to followup after the procedures. The characteristics of 81 patients with HCC were well balanced between the two groups (Table 1). A total of 42 patients in the study group underwent CIK cell immunotherapy, of whom 12 patients received CIK cells via common hepatic artery and 30 patients received CIK cells via peripheral veins. In addition, 10 patients received 8 infusions and 4 patients received 12 infusions.
In the control group, no downtrend of AFP concertration was observed when comparing AFP concentrations during followup after TACE and the combined RFA procedure to baseline levels at inclusion (Figure 1 ). In the study group where minimally invasive therapy was combined with CIK therapy, AFP concentrations during followup gradually decreased when comparing to baseline levels before inclusion, and AFP levels were maintained when it was reduced to lower concentrations (Figure 2 ). The differences in AFP concentrations at various .00 1.00 3.00 5.00 7.00 9.00 10.00 11.00 12.00 Time (months) I O followup time points were significant between the t wo groups (Table 2 ).
In the study group, results of detections of T lymphocyte subsets in peripheral blood before and after CIK cell therapy were as follows. + T cells ratio significantly increased. These values evolved from 28.1 依 5.9, 32.9 依 8.4, and 0.93 依 0.32, respectively, before therapy to 32.7 依 3.6, 28.8 依 2.2, and 1.16 依 0.19, respectively, after therapy ( values were < 0.001, = 0.046, and = 0.004, respectively).
In the study group, with combined CIK cell therapy, the HBVDNA content was higher than 1.0 × 10 3 copies/mL in 15 patients, while only in 4 patients after therapy. Among these, the HBVDNA content was within the range of 1.0 伊 10 3 1.0 伊 10 6 copies/mL in 14 patients, while only in 3 patients after therapy. In one patient whose HBVDNA content was more than 1.0 伊 10 6 copies/mL before therapy, the value was 1.6 伊 10 4 copies/mL after therapy. As for the control group, the HBVDNA content before therapy was higher than 1.0 伊 10 3 copies/mL in 11 patients. During the 1year followup, the HBVDNA content was reduced from 1.1 伊 10 5 copies/mL before therapy to less than 1.0 伊 10 3 copies /mL after therapy in only one patient.
All patients were followed up for more than 1 year. In the control group, 9 patients developed recurrence within 1 year, of whom 6 patients had an AFP concentration slightly higher than the reference value after the procedures. The mean AFP concentration was 28.03 依 6.44 ng/mL, and time to recurrence was 4.3 months, 5.4 months, 6.2 months, 7.0 months, 7.6 months, and 10.3 months, respectively. In the study group, 3 patients had recurrence within the 1year followup, of whom 2 patients had AFP concentration slightly higher than the reference value after the procedures. After CIK cell immunotherapy, AFP concentrations reduced in all patients, but mean AFP value was more than 5 ng/mL. Time to recurrence was 9.4 months and 11.2 months, respectively, after CIK cell therapy.
The 1year recurrence rate was 23.1% (9/39) for the study group and 7.14% (3/42) for the control group ( = 0.04). After curative TACE and the combined RFA procedure, the recurrence rate in patients with AFP concentration slightly higher than the reference value significantly decreased in the adjuvant CIK cell therapy group (the study group) as compared to the control group (20% vs. 66.67%), and time to recurrence was shortened No downtrend of AFP concentration was observed in the control group when comparing AFP concentration during follow鄄 up to baseline levels at randomization.
After the trentment with CIK cells, the downtrend of AFP concentration was observed in study group compared with baseline levels at randomization.
as compared to the control group as well (average 6.8 months vs. 10.2 months).
AFP is currently widely recognized as a tumorrelated antigen for HCC, with extremely complicated biologic activities. While its exact biologic function is still unclear, it may be related to tumor occurrence and development. In adults its serum level is fairly low, approximately 510 ng/mL, but cancerous hepatic cells can synthesize AFP [14] . Theoretically, since the halflife of AFP is less than 5 days, AFP levels may decrease to normal levels at approximately 30 days (about 56 halflives) after effective curative treatment in AFPpositive HCC [15] . But concomitant infection with HBV and impairment from hepatic sclerosis and in the hepatic parenchyma are also factors that lead to increase of AFP levels [1618] . In addition, it is also possible that there may be micrometastatic lesions or residual cancer cells derived from HCC colony in blood circulation, therefore AFP expression change to negative in only 80.3% of patients even after surgery [19] .
In this study, AFP expression change to negative in 76.5%
(62/81) of the patients at 68 weeks after curative minimally invasive therapy in a group of patients with AFP positive HCC, which was consistent with the reported literature [19] . In our study, the reasons why AFP was slightly higher than normal after curative minimally invasive therapy in some patients might include the mechanisms mentioned above. These factors were well balanced in the distribution between the two groups of patients. While after CIK cell therapy, serum AFP level in the patients decreased further, the pathway by which AFP decreased might therefore be related to the CIK cell therapy. The results of our study primarily demonstrated the effect of CIK cell therapy in reducing shortterm (1year) recurrence after minimally invasive therapy for HCC. After curative minimally invasive therapy for HCC, the recurrence rate within 1 year in patients with an AFP level slightly higher than the reference value after the procedures was lower in the CIK cell therapy group (the study group) than in the control group, and time to recurrence was prolonged as well. These indicate that further and continued decreases in AFP concentrations after CIK cell therapy might be the pathway via which CIK cells exert their roles in preventing shortterm recurrence, and that further and continued decreases in AFP concentrations might be a candidate marker to predict the clinical efficacy of CIK cells as adjuvant therapy for minimally invasive therapy for patients with HCC.
Studies have suggested that AFP expressed by hepatic cancer cells are endowed with the activity of inducing apoptosis in lymphocytes and inhibiting immune functions [20] , while immune hypofunction is an important reason for the susceptibility to HCC recurrence and metastasis. AFP may inhibit immune function in the body by altering the ratio of CD4 + and CD8 + T lymphocyte subsets and inducing lymphocyte death [21, 22] . the results from previous studies [9] . That is, the changes in T lymphocyte subsets reflected improvement at various degrees in immune function of the body, and immune suppression on the body by tumor cells was attenuated and antitumor capacity was enhanced. These effects may be very important in inhibiting tumor recurrence and metastasis [2] . We deduced that the improvement in immune function resulting from the CIK cell therapy might be partly due to the decrease in AFP. Such change prevented AFP from inhibiting immune functions by altering the ratio of CD4 + and CD8 + T lymphocyte subsets.
AFP expressed by hepatic cancer cells may also be an important endogenous autocrine protein that promotes tumor cell proliferation [23] . Such activity in promoting cancer cell growth is not only due to the immune suppression of AFP, but also because AFP accelerates the transformation from G 0 phase cells to Sphase cells and significantly prompts DNA synthesis. The expression of oncogenes, such as p53, cfos, cjun, and Nras, also increases in AFPtreated cells [24] . Hence, the mechanism via which CIK cells reduced and delayed tumor recurrence in the study group might be that CIK cell therapy could reduce serum AFP concentrations and interrupt the promotion of AFP on cancer cell growth. Even though there were small amounts of residual tumor cells in the body, the absence of adequate promotion on cancer cell growth delayed tumor recurrence and metastasis.
Moreover, studies have suggested that AFP may induce hepatic cancer cells to escape from immune surveillance in the body. Its mechanisms may be related to AFP helping hepatic cancer cells escape from immune surveillance by numerous mechanisms, including influencing the expression of the Fas/FasL system in hepatic cancer cells via P53 and regulating the expression of tumor necrosis factor (TNF) receptors [25, 26] .
Therefore, decreases in AFP concentrations may prevent hepatic cancer cells from escaping from immune surveillance, and thus allow endogenous immunity and/or exogenous immunotherapy to fully exert their effects in eradicating residual tumor cells and reducing or preventing the recurrence and metastasis given rise by immunetolerant cells. Such an AFPrelated mechanism may be another mechanism via which CIK cell therapy delays tumor recurrence and metastasis. Previous studies have demonstrated that adoptive cell immunotherapy in patients after surgical resection for HCC could reduce the recurrent rate of HCC, and its mechanisms may be related to CIK cell therapy directly eradicating cancer microlesions, counteracting HBV, and improving immune function [8] . In this study, it was observed that CIK cell therapy presented good efficacy in reducing shortterm tumor recurrence.
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